Vraylar vs. Invega
See how Vraylar and Invega compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Vraylar is FDA-approved for four conditions (schizophrenia, bipolar mania, bipolar depression, and add-on MDD), while Invega covers only schizophrenia and schizoaffective disorder.
Invega offers long-acting injectable versions given monthly, every three months, or every six months, while Vraylar comes only as a daily oral capsule.
Both drugs carry a boxed warning for increased risk of death in elderly patients with dementia-related psychosis, a use neither is approved for.
Vraylar vs. Invega Drug Summary
Vraylar
Vraylar (cariprazine) is an atypical antipsychotic taken as a once-daily oral capsule, with or without food. It is FDA-approved for schizophrenia, manic or mixed episodes of bipolar I disorder, depressive episodes of bipolar I disorder, and as an add-on to antidepressants for major depressive disorder.
Invega
Invega (paliperidone) is an atypical antipsychotic taken as a once-daily oral extended-release tablet. It is FDA-approved for schizophrenia in adults and adolescents ages 12 to 17, and for schizoaffective disorder in adults, as monotherapy or added to mood stabilizers and antidepressants.
Vraylar vs. Invega Side Effects
Vraylar
Invega
Vraylar vs. Invega Dosage
Vraylar
Invega
| STAGE | DOSE | WHEN |
| Starting dose | 1.5 mg once daily | Day 1 |
| Maximum dose | 6 mg once daily | If needed |
| Dose changes | 3 increases | Every day |
| STAGE | DOSE | WHEN |
| Starting dose | 3 mg once daily | At the start |
| Maximum dose | 12 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Vraylar
| STAGE | DOSE | WHEN |
| Starting dose | 1.5 mg once daily | Day 1 |
| Maximum dose | 6 mg once daily | If needed |
| Dose changes | 3 increases | Every day |
Invega
| STAGE | DOSE | WHEN |
| Starting dose | 3 mg once daily | At the start |
| Maximum dose | 12 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Vraylar vs. Invega Indications
Vraylar
Vraylar covers a broad range of approved uses: schizophrenia, bipolar I mania or mixed episodes, bipolar I depression, and add-on therapy for major depressive disorder. It is approved for adults, with additional pediatric indications for schizophrenia and bipolar mania.
Schizophrenia in adults and adolescents 13+
Manic or mixed bipolar I episodes (adults and youth 10+)
Depressive episodes of bipolar I disorder (adults)
Add-on therapy for major depressive disorder (adults)
Not approved for schizoaffective disorder (off-label only)
Invega
Invega is approved for schizophrenia in adults and adolescents ages 12 to 17, and for schizoaffective disorder in adults, either alone or combined with mood stabilizers and antidepressants. It has been available since 2006 and also comes in long-acting injectable versions for maintenance treatment.
Schizophrenia in adults and adolescents 12-17
Schizoaffective disorder in adults, as monotherapy
Schizoaffective disorder as add-on to mood stabilizers/antidepressants
Not approved for bipolar disorder or depression
Not approved for dementia-related psychosis
Vraylar vs. Invega Pros and Cons
Vraylar
Vraylar's broad FDA approval across schizophrenia, bipolar mania, bipolar depression, and adjunctive MDD gives prescribers more flexibility than most antipsychotics. As a newer brand-only drug, it has no generic option, which can affect insurance coverage for some patients.
Pros
FDA-approved for bipolar depression and add-on MDD, not just schizophrenia
D3-receptor activity may help with negative symptoms of schizophrenia
Long half-life means a single missed dose is less likely to cause a gap in coverage
Cons
Only available as a daily oral capsule, no long-acting injectable option
No generic version currently available, unlike many older antipsychotics
Not approved for schizoaffective disorder; that use is off-label only
Invega
Invega's OROS tablet and long-acting injectable formulations make it a flexible option for patients who struggle with daily pill-taking. Its narrower FDA approval covers schizophrenia and schizoaffective disorder only, without coverage for mood episodes.
Pros
Available as long-acting injectables given monthly, every 3, or every 6 months
FDA-approved for schizoaffective disorder, unlike Vraylar
Longer track record, FDA-approved since 2006
Cons
Not approved for bipolar disorder or major depressive disorder
Requires dose adjustment based on kidney function
Tablet shell may pass intact into stool, which can concern some patients
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.